BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saleh NM, Abdel-Rahman AA, Omar AM, Khalifa MM, El-Adl K. Pyridine-derived VEGFR-2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking. Arch Pharm (Weinheim) 2021;354:e2100085. [PMID: 33948983 DOI: 10.1002/ardp.202100085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 El-Adl K, Sakr HM, Yousef RG, Mehany ABM, Abulkhair HS, Eissa IH. New quinoxalin-2(1H)-one-derived VEGFR-2 inhibitors: Design, synthesis, in vitro anticancer evaluations, in silico ADMET, and docking studies. Arch Pharm (Weinheim) 2022;:e2200048. [PMID: 35437829 DOI: 10.1002/ardp.202200048] [Reference Citation Analysis]
2 El-Adl K, Ibrahim MK, Khedr F, Abulkhair HS, Eissa IH. Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors. Arch Pharm (Weinheim) 2021;:e2100278. [PMID: 34596910 DOI: 10.1002/ardp.202100278] [Reference Citation Analysis]
3 Desai N, Monapara J, Jethawa A, Khedkar V, Shingate B. Oxadiazole: A highly versatile scaffold in drug discovery. Arch Pharm (Weinheim) 2022;:e2200123. [PMID: 35575467 DOI: 10.1002/ardp.202200123] [Reference Citation Analysis]
4 Abdelgawad MA, El-adl K, El-hddad SSA, Elhady MM, Saleh NM, Khalifa MM, Khedr F, Alswah M, Nayl AA, Ghoneim MM, Abd El-sattar NEA. Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2,4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPARγ Agonists. Pharmaceuticals 2022;15:226. [DOI: 10.3390/ph15020226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Singh VJ, Sharma B, Chawla PA. Recent developments in mitogen activated protein kinase inhibitors as potential anticancer agents. Bioorg Chem 2021;114:105161. [PMID: 34328852 DOI: 10.1016/j.bioorg.2021.105161] [Reference Citation Analysis]
6 Eissa IH, Ibrahim MK, Alesawy MS, El-Adl K. Antiproliferative evaluations of triazoloquinazolines as classical DNA intercalators: Design, synthesis, ADMET profile, and molecular docking. Arch Pharm (Weinheim) 2022;:e2100487. [PMID: 35194810 DOI: 10.1002/ardp.202100487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Alesawy MS, Ibrahim M, Eissa IH, El‐adl K. Design, synthesis, in silico ADMET, docking, and antiproliferative evaluations of [1,2,4]triazolo[4,3‐ c ]quinazolines as classical DNA intercalators. Archiv der Pharmazie. [DOI: 10.1002/ardp.202100412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
8 Eliwa EM, Frese M, Halawa AH, Soltan MM, Ponomareva LV, Thorson JS, Shaaban KA, Shaaban M, El-agrody AM, Sewald N. Metal-free domino amination-Knoevenagel condensation approach to access new coumarins as potent nanomolar inhibitors of VEGFR-2 and EGFR. Green Chemistry Letters and Reviews 2021;14:578-99. [DOI: 10.1080/17518253.2021.1981462] [Reference Citation Analysis]
9 Elkaeed EB, Yousef RG, Elkady H, Gobaara IMM, Alsfouk AA, Husein DZ, Ibrahim IM, Metwaly AM, Eissa IH. The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1H-Indole Derivative: In Silico and In Vitro Approaches. Processes 2022;10:1391. [DOI: 10.3390/pr10071391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Khalifa MM, Al-Karmalawy AA, Elkaeed EB, Nafie MS, Tantawy MA, Eissa IH, Mahdy HA. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies. J Enzyme Inhib Med Chem 2022;37:299-314. [PMID: 34894955 DOI: 10.1080/14756366.2021.2007905] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
11 El-Adl K, Abdel-Rahman AA, Omar AM, Alswah M, Saleh NM. Design, synthesis, anticancer, and docking of some S- and/or N-heterocyclic derivatives as VEGFR-2 inhibitors. Arch Pharm (Weinheim) 2021;:e2100237. [PMID: 34862655 DOI: 10.1002/ardp.202100237] [Reference Citation Analysis]
12 Elkady H, Elwan A, El-Mahdy HA, Doghish AS, Ismail A, Taghour MS, Elkaeed EB, Eissa IH, Dahab MA, Mahdy HA, Khalifa MM. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. J Enzyme Inhib Med Chem 2022;37:397-410. [PMID: 34961427 DOI: 10.1080/14756366.2021.2015343] [Reference Citation Analysis]